Biotechnology
Vertex Pharmaceuticals reported a 12.5% revenue increase in Q2 FY2026 driven by its cystic fibrosis franchise and strong early sales of new therapies CASGEVY and JOURNAVX, while announcing a $10 billion acquisition of Crinetics Pharmaceuticals to expand its pipeline.
Key risk: Crinetics Acquisition Integration Risk
Vertex may be unable to complete the Crinetics acquisition or integrate its business, and the anticipated benefits depend on PALSONIFY sales and atumelnant development success, posing a material adverse risk.
Other Biotechnology companies